Ellison Cancels $7.5B Oracle Sale Plan With Zero Shares Sold

Larry Ellison canceled his plan to sell Oracle stock. The termination was disclosed on Sept. 12, 2026. No stock was sold under the plan. Ellison has no other plans to sell any of his Oracle stock. Announcement

The canceled program covered up to 50 million Oracle shares, with a stated value of up to $7.5 billion. FT The structure was described as a trading plan. Ellison adopted it on June 22. It was scheduled to run through Oct. 24. Those calendar details were disclosed in a regulatory filing. CNBC

The sequence runs from adoption in June to public reporting in September to termination disclosed in September. The lifecycle ends with no executed sales to settle, reconcile or report. It also ends with no residual authorization outstanding under the disclosure as made.

For price context, Oracle investor relations historical stock data listed ORCL at $175.07 on June 22, 2026. Oracle Investor Relations That print is background only. It does not establish execution levels, because execution never occurred.

Looking at what this means for positioning, the immediate effect is removal of a defined overhang — a known block of shares that could have been sold. Desks tracking potential insider supply through Oct. 24 no longer have a scheduled seller to model. Float, the shares available for public trading, is unchanged. Settlement pipelines are clear. Volatility assumptions tied to mechanical selling lose their anchor.

The broader context here involves execution certainty. A plan that authorizes sales over a window creates a contingent supply schedule, a possible stream of sales traders must allow for. Market makers, securities lenders and derivatives desks price that possibility even before any shares trade. Cancellation with zero execution removes the contingency entirely. There is nothing left to hedge or finance for this seller.

In my view, the second-order question is signaling versus mechanics. A termination with zero fills and an explicit statement of no further sale plans closes the loop cleanly from a disclosure perspective. It does not create new information about fundamentals, capital allocation or governance. For portfolio construction, the prudent read is narrow. Expected supply is zero. Realized supply was zero. Everything else is interpretation of intent, which the filing does not supply.

Looking at liquidity, the effects should not be overstated. Removal of overhang does not add buying pressure. It subtracts potential selling pressure. Price discovery reverts to operating performance, rates and sector flows. Positioning that leaned short into expected supply, or deferred buying pending execution, may adjust. That adjustment is flow driven, not fundamental. Risk models can drop the calendar overhang factor. Tracking lists require no further action. Attention shifts back to earnings, guidance and macro variables.